OtherNeuropharmacology
THE NOVEL MELATONIN AGONIST, AGOMELATINE (S20098), IS AN ANTAGONIST AT 5-HYDROXYTRYPTAMINE2C RECEPTORS, BLOCKADE OF WHICH ENHANCES THE ACTIVITY OF FRONTOCORTICAL DOPAMINERGIC AND ADRENERGIC PATHWAYS
Mark J. Millan, Alain Gobert, Françoise Lejeune, Anne Dekeyne, Adrian Newman-Tancredi, Valérie Pasteau, Jean-Michel Rivet and Didier Cussac
Journal of Pharmacology and Experimental Therapeutics May 15, 2003, DOI: https://doi.org/10.1124/jpet.103.051797
Mark J. Millan
Alain Gobert
Françoise Lejeune
Anne Dekeyne
Adrian Newman-Tancredi
Valérie Pasteau
Jean-Michel Rivet
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
OtherNeuropharmacology
THE NOVEL MELATONIN AGONIST, AGOMELATINE (S20098), IS AN ANTAGONIST AT 5-HYDROXYTRYPTAMINE2C RECEPTORS, BLOCKADE OF WHICH ENHANCES THE ACTIVITY OF FRONTOCORTICAL DOPAMINERGIC AND ADRENERGIC PATHWAYS
Mark J. Millan, Alain Gobert, Françoise Lejeune, Anne Dekeyne, Adrian Newman-Tancredi, Valérie Pasteau, Jean-Michel Rivet and Didier Cussac
Journal of Pharmacology and Experimental Therapeutics May 15, 2003, DOI: https://doi.org/10.1124/jpet.103.051797
OtherNeuropharmacology
THE NOVEL MELATONIN AGONIST, AGOMELATINE (S20098), IS AN ANTAGONIST AT 5-HYDROXYTRYPTAMINE2C RECEPTORS, BLOCKADE OF WHICH ENHANCES THE ACTIVITY OF FRONTOCORTICAL DOPAMINERGIC AND ADRENERGIC PATHWAYS
Mark J. Millan, Alain Gobert, Françoise Lejeune, Anne Dekeyne, Adrian Newman-Tancredi, Valérie Pasteau, Jean-Michel Rivet and Didier Cussac
Journal of Pharmacology and Experimental Therapeutics May 15, 2003, DOI: https://doi.org/10.1124/jpet.103.051797
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement